Aktis Oncology announced on Tuesday a collaboration with Eli Lilly ($LLY) to develop novel anticancer radiopharmaceuticals. The partnership makes Aktis eligible for milestone payments of up to $1.1 billion and royalties on sales. The deal includes a $60 million upfront payment. This collaboration follows Eli Lilly's acquisition of Point Biopharma for $1.4 billion last year, further deepening Lilly's investment in radiopharmaceuticals.
Lilly partners with Aktis, deepening radiopharma investment https://t.co/ucM0CBypQi $LLY by @Lilah_Alvarado
Aktis Oncology said today that it's struck an agreement with Eli Lilly to discover new radiopharmaceuticals. This comes after Lilly acquired radiopharma company Point Biopharma for $1.4 billion last year. https://t.co/kPbGW4KBZL
Lilly partners with Aktis, deepening radiopharma investment https://t.co/7welnGwMJX by @Lilah_Alvarado $LLY $NVS $BMY
Aktis to collaborate with Eli Lilly on cancer therapies https://t.co/owjhpV8M0I https://t.co/NAbUyA6L0E
AKTIS ONCOLOGY ENTERS INTO STRATEGIC COLLABORATION WITH LILLY $LLY TO DISCOVER AND DEVELOP NOVEL ANTICANCER RADIOPHARMACEUTICALS #RLT 60m$ upfront https://t.co/gOgzBy1x2u
Aktis Oncology said on Tuesday it will collaborate with Eli Lilly to develop cancer therapies, making it eligible for milestone payments of up to $1.1 billion and royalties on sales. https://t.co/WbiNoOLtfQ https://t.co/WbiNoOLtfQ